As previously reported, Craig-Hallum initiated coverage of MaxCyte with a Buy rating and $7 price target. The firm believes MaxCyte’s razor-razor blade business model is on the verge of taking off and encourages investors to own this stock. With a key platform for discovery and manufacturing of cell and gene therapies, a strong balance sheet, and a PDUFA date on Dec. 8 that could provide further validation, Craig-Hallum believes the stage is set for a rally in the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MXCT: